[1] |
HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong.
Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
|
[2] |
ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge.
Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
|
[3] |
QIAN Jin, WANG Fengyan.
Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
|
[4] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|
[5] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[6] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
[7] |
PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua.
Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
|
[8] |
YU Yahong, SONG Yu.
Pharmacotherapy of patients with left ventricular assist devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 198-204.
|
[9] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[10] |
PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu.
Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
|
[11] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
[12] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
[13] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
[14] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|
[15] |
PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng.
Progress of pharmacotherapy for heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
|